Role of matrix metalloproteinase 9 gene polymorphism as genetic risk factor for lung cancer

Abstract

Lung cancer (LC) is one of the most incident malignancies worldwide. This study investigated the potential role of matrix metalloproteinase9 gene (MMP9) single nucleotide polymorphisms (SNPs) in Lung cancer patients. The study population was included 75 Iraqi patients with confirmed Lung cancer and 25 healthy people as controls. In this study, the -1562 C/T polymorphism in MMP9 gene was detected by restriction fragment length polymorphism-polymerase chain reaction (RFLP-PCR) technique. The genotype distribution results of the -1562 C/T SNP of MMP9 gene have shown no significant differences (p>0.05) between controls (CC: n= 15, 60%; CT: n=9, 36%; TT: n=1, 4%) and Lung cancer patients (CC: n= 44, 58.66%; CT: n=30, 40%; TT: n=1, 1.34%). Results of the association analysis between genotype distribution of the -1562 C/T SNP of MMP9 gene and clinicopathological criteria of cases such as histological grading, TNM staging and lymph node metastasis, had shown no significant association (p>0.05). While analysis of the association between genotype distribution of the -1562 C/T SNP of MMP9 gene and smoking status among patients were statically significant (p<0.05). These results suggested that the SNP in MMP9 gene was involved in lung cancer progression, tissue invasion and metastasis involvement.